MedTrace Logo

L-arginine for Prevention of Kidney Damage in Liver Transplant Recipients

NCT00587418 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2012-09-03

No results posted yet for this study

Summary

Chronic renal insufficiency is a common and important health problem that causes morbidity and mortality among patients who have undergone liver transplantation. It is mainly caused by drugs (calcineurin inhibitors) that are used to prevent or treat rejection and once established, there is no effective treatment. This research investigates whether L-arginine can reverse the effects of calcineurin inhibitors on the kidneys and thus prevent renal insufficiency in liver transplant recipients.

Conditions

  • Liver Transplant Recipients

Interventions

DIETARY_SUPPLEMENT

L-arginine

Arginaid (Novartis) 1 package (9.2g) bid for 7 days

DIETARY_SUPPLEMENT

Placebo

Placebo powder 9.2g bid for 7 days

Sponsors & Collaborators

  • National Center for Complementary and Integrative Health (NCCIH)

    collaborator NIH

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • W. Ray Kim · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2011-07-31
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00587418 on ClinicalTrials.gov